Retension Pharmaceuticals (NASDAQ:RTSN) Releases Quarterly Earnings Results

Retension Pharmaceuticals logo with background
Image from MarketBeat Media, LLC.

Key Points

  • Retension reported a quarterly loss of $7.33 per share.
  • Shares rose $0.74 to $12.15 on Wednesday. Analysts’ consensus rating was Buy, with a $52.50 average price target.
  • CEO Eric L. Keller and Director Franklin M. Berger each bought shares at $12 per share, purchasing 20,800 and 10,000 shares, respectively.
  • MarketBeat previews top five stocks to own in December.

Retension Pharmaceuticals (NASDAQ:RTSN - Get Free Report) posted its earnings results on Wednesday. The company reported ($7.33) EPS for the quarter, Zacks reports.

Retension Pharmaceuticals Price Performance

Shares of Retension Pharmaceuticals stock traded up $0.74 during trading on Wednesday, hitting $12.15. 32,365 shares of the company's stock were exchanged, compared to its average volume of 121,834. Retension Pharmaceuticals has a 52-week low of $9.66 and a 52-week high of $18.64.

Analyst Ratings Changes

Several analysts have recently commented on RTSN shares. Wall Street Zen upgraded Retension Pharmaceuticals to a "hold" rating in a report on Saturday. Zacks Research started coverage on Retension Pharmaceuticals in a research report on Wednesday, November 4th. They set a "hold" rating on the stock. Guggenheim started coverage on Retension Pharmaceuticals in a research note on Monday, November 2nd. They issued a "buy" rating and a $55.00 price target for the company. Oppenheimer initiated coverage on Retension Pharmaceuticals in a research note on Tuesday, November 3rd. They set an "outperform" rating and a $50.00 price target on the stock. Finally, Leerink Partners initiated coverage on shares of Retension Pharmaceuticals in a research report on Tuesday, November 3rd. They issued a "strong-buy" rating for the company. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Retension Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $52.50.

Read Our Latest Analysis on Retension Pharmaceuticals

Insider Buying and Selling

In other news, Director Franklin M. Berger acquired 10,000 shares of the company's stock in a transaction dated Tuesday, October 13th. The shares were acquired at an average price of $12.00 per share, with a total value of $120,000.00. Following the purchase, the director directly owned 10,000 shares of the company's stock, valued at $120,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Eric L. Keller bought 20,800 shares of the business's stock in a transaction dated Tuesday, October 13th. The shares were purchased at an average cost of $12.00 per share, with a total value of $249,600.00. Following the completion of the acquisition, the chief executive officer owned 423,377 shares in the company, valued at approximately $5,080,524. This represents a 5.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

About Retension Pharmaceuticals

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Retension Pharmaceuticals Right Now?

Before you consider Retension Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Retension Pharmaceuticals wasn't on the list.

While Retension Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines